2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow BRAF Gene Mutation: new trials by email Literature Review of BRAF Gene Mutation trials Research Report on BRAF Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Dabrafenib, Trametinib - Ameloblastoma, BRAF Gene Mutation | Phase 2 | Completed | Stanford University | 1 | 2017-07-17 | 2024-01-30 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
Adamantinoma (1) · Ameloblastoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Squamous Cell Carcinoma of Head and Neck (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Bone Diseases (1) · Bone Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Musculoskeletal Diseases (1) · Neoplasms, Glandular and Epithelial (1) · Odontogenic Tumors (1)
dabrafenib (1) · pembrolizumab (1) · trametinib (1)
Stanford University (1) · University of Southern California (1)
United States (2)
Alexander Colevas (1) · Jorge Nieva, MD (1)
P30CA014089 (1)